Rehermann B - Search Results

1

Integrating natural commensals and pathogens into preclinical mouse models.

Rehermann B, Graham AL, Masopust D, Hamilton SE. Rehermann B, et al. Nat Rev Immunol. 2024 Nov 19. doi: 10.1038/s41577-024-01108-3. Online ahead of print. Nat Rev Immunol. 2024. PMID: 39562646 Review.

2

Toward a better understanding of chronic hepatitis B virus infection.

Rehermann B. Rehermann B. J Clin Invest. 2024 Oct 1;134(19):e185568. doi: 10.1172/JCI185568. J Clin Invest. 2024. PMID: 39352391 Free PMC article. No abstract available.

3

Leveraging dirty mice that have microbial exposure to improve preclinical models of human immune status and disease.

Liu Q, Pickett T, Hodge D, Rios C, Arnold M, Dong G, Hamilton SE, Rehermann B. Liu Q, et al. Among authors: rehermann b. Nat Immunol. 2024 Jun;25(6):947-950. doi: 10.1038/s41590-024-01842-9. Nat Immunol. 2024. PMID: 38750319 No abstract available.

4

Sexual dimorphism in skin immunity is mediated by an androgen-ILC2-dendritic cell axis.

Chi L, Liu C, Gribonika I, Gschwend J, Corral D, Han SJ, Lim AI, Rivera CA, Link VM, Wells AC, Bouladoux N, Collins N, Lima-Junior DS, Enamorado M, Rehermann B, Laffont S, Guéry JC, Tussiwand R, Schneider C, Belkaid Y. Chi L, et al. Among authors: rehermann b. Science. 2024 Apr 12;384(6692):eadk6200. doi: 10.1126/science.adk6200. Epub 2024 Apr 12. Science. 2024. PMID: 38574174

5

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.

Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Ghany MG, et al. J Hepatol. 2023 Nov;79(5):1254-1269. doi: 10.1016/j.jhep.2023.06.002. Epub 2023 Jun 21. J Hepatol. 2023. PMID: 37377088 Review.

6

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.

Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Ghany MG, et al. Hepatology. 2023 Nov 1;78(5):1654-1673. doi: 10.1097/HEP.0000000000000431. Epub 2023 Jun 21. Hepatology. 2023. PMID: 37326326

7

Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C.

Nishio A, Hasan S, Park H, Park N, Salas JH, Salinas E, Kardava L, Juneau P, Frumento N, Massaccesi G, Moir S, Bailey JR, Grakoui A, Ghany MG, Rehermann B. Nishio A, et al. Among authors: rehermann b. Nat Commun. 2022 Sep 16;13(1):5446. doi: 10.1038/s41467-022-33035-z. Nat Commun. 2022. PMID: 36114169 Free PMC article.

8

A Rare Case of Recurrent Intrahepatic Cholestasis of Pregnancy With Prolonged Postpartum Hepatic Inflammation Despite Normalization of Bile Acid Levels.

Shah PA, Nishio A, Hasan S, Wu L, Chie L, Rehermann B, Lau DT. Shah PA, et al. Among authors: rehermann b. Gastro Hep Adv. 2022 Sep 7;2(1):46-48. doi: 10.1016/j.gastha.2022.08.011. eCollection 2023. Gastro Hep Adv. 2022. PMID: 39130143 Free PMC article.

9

Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.

Lai CW, Nishio A, Hasan S, Kefalakes H, Rehermann B, Ghany MG. Lai CW, et al. Among authors: rehermann b. Hepatology. 2021 Dec;74(6):3552-3553. doi: 10.1002/hep.32205. Hepatology. 2021. PMID: 34662444 No abstract available.

10

Natural versus Laboratory World: Incorporating Wild-Derived Microbiota into Preclinical Rodent Models.

Oh JH, Rehermann B. Oh JH, et al. Among authors: rehermann b. J Immunol. 2021 Oct 1;207(7):1703-1709. doi: 10.4049/jimmunol.2100426. J Immunol. 2021. PMID: 34544812 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters